Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

Upadacitinib may cause hair loss.

The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.

New treatments for severe alopecia areata show promise but lack standard approval.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Upadacitinib improved multiple immune-related conditions in one patient.

A combined treatment with microneedling and vitamin D3 led to complete hair regrowth in a woman with stubborn patch alopecia areata.

Baricitinib effectively regrows hair in severe alopecia areata cases.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.

Baricitinib is effective and safe for treating severe alopecia areata.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Upadacitinib may effectively treat alopecia areata without side effects.

Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.

Melatonin affects certain genes and pathways involved in cashmere goat hair growth.

Melatonin can increase cashmere yield by altering gene expression and restarting the growth cycle early.

Rabbits with high wool production have more hair follicles, influenced by specific long noncoding RNAs.

Long noncoding RNAs help regulate hair follicle density in rabbits.

A 589 nm laser increases IL-2 and IFN-y gene expression in human T-cells.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Type I interferons play a key role in the development of various skin diseases.

Ruxolitinib treatment may cause eyelash growth.

Several new treatments for different types of hair loss show promise in improving patient quality of life.

Alopecia Areata is an autoimmune disease causing hair loss, with no cure yet, but research may lead to new treatments.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

PPARα agonists may help treat alopecia areata by reducing inflammation.